


meibomask®

Photobiomodulation
champion.



RESOURCES



DOWNLOAD ↓
BIBLIOGRAPHY

[espansionegroup.it/
bibliography](https://espansionegroup.it/bibliography)



DOWNLOAD ↓
BROCHURE

espansionegroup.it

meibomask®

Photobiomodulation champion.

meibomask® is our answer to professionals that want to focus on the unique benefits of our LM® LLLT technology for the treatment of most ocular surface diseases.


Light Modulation® Low Level Light Therapy LM® LLLT

LM® LLLT is our patented photobiomodulation technology —it works by triggering endogenous heating of both eyelids, stimulating ATP production within mitochondria. It enables us to optimally treat MGD and many other ocular surface pathologies.



LM® LLLT Benefits

- Fast**
> A treatment lasts 15'
- Painless**
> It grants immediate relief to the patient
- Plug&Play**
> It doesn't require the operator to be constantly present during the treatment
- Easy and Safe**
> For the operator
- Direct Treatment**
> It enables a full therapy, covering both lower and upper eyelids to grant maximum efficacy
- Upgradable**
> Always Up to Date



LM® LLLT can be leveraged employing three different light frequencies—each with its own unique benefits and use cases.



Red Light
OPHTHALMOLOGY USE: CHALAZION, STYE, BLEPHARITIS, PRE-/POST-REFRACTIVE AND CATARACT SURGERY

> Scientific Coverage




G. GIANNACCARE
Italy,
MD, PHD, FEBO

■ LLLT ■ CONTROL


“

Two sessions of LLLT performed one week **before and after cataract surgery** were effective in ameliorating tear film stability and ocular discomfort symptoms.

OSDI > LOW IS BETTER



NIBUT > HIGHER IS BETTER



SOURCE:

GIANNACCARE, Giuseppe et al. Outcomes of LLLT for the prophylaxis of Iatrogenic Dry Eye after Cataract Surgery: A Prospective Randomized Double-Masked Controlled Clinical Trial. British Journal of Ophthalmology, May 2023.